2014 Webcasts

The webcasting from HIV Drug Therapy Glasgow is supported by an unrestricted financial contribution from Viiv Healthcare.

Full Scientific Programme including abstracts submitted for oral presentation now available.  Click the link to view HIV Glasgow Programme

Abstracts accepted for Poster Presentation now available.  Click the link to view HIV Glasgow Poster Listing

See the Industry Involvement tab for details of Industry Symposia taking place during the meeting.

Sunday 2 November
Monday 3 November
Tuesday 4 November
Wednesday 5 November
Thursday 6 November

Introduction

As webcasts illustrating the invited plenary and case studies, submitted papers and poster discussions from the Congress become available they are being added to the Scientific Programme below.  Please link on the MAC/PC links beside each presentation title. For webcasts and abstracts from previous meetings please visit Webcasts and Abstracts

The following specifications are recommended to avoid play back issues.
PC – Click the link (PC) Internet Explorer 7 or above Screen resolution of 1024 x 768 or higher Internet bandwidth of 750 kbps or higher
MAC – Click the link (MAC) Mac OS x 10.4.8 or later Safari 2.0.4 or later Screen resolution of 1024 x 768 or higher Internet bandwidth of 750 kbps or higher


Sunday 2 November

Managing Patients on Multiple Co-medications PC / MAC
In collaboration with The University of Liverpool Drug Interactions Website:
www.hiv-druginteractions.org
Welcome and introduction
David Back, University of Liverpool, Liverpool, UK
Debate: DDIs will not be a concern in 2015
Jonathan Schapiro, National Hemophilia Center, Tel Aviv, Israel
Manuel Battegay, Division of Infectious Diseases, University Hospital Basel, Basel, Switzerland
Case Studies
Led by Saye Khoo, University of Liverpool, Liverpool, UK
Case 1: HIV-HCV co-infection
Sanjay Bhagani, Royal Free Hospital, London, UK
Case 2: Recreational drugs and ARVs
Marta Boffito, Chelsea and Westminster Hospital, London, UK
Case 3: TB therapy (including MDR and XDR TB) and ARVs
Kelly Dooley, Johns Hopkins University School of Medicine, Baltimore, USA
Debate re-visited. Any change of mind?
Jonathan Schapiro and Manuel Battegay
Closing remarks

Official Opening
Ian Weller, University College London, London, UK PC / MAC
Welcome from Glasgow City
Presentation of Thai Scholarship in memory of Khanokporn Satjawat PC / MAC
Ian Weller

Keynote Lectures
Curbing the epidemic on both sides of the Atlantic: a public health perspective
Kevin A Fenton, Health and Wellbeing, Public Health England, London, UK PC / MAC
Mechanisms underlying abnormalities of immune activation/coagulation in HIV infection
Clifford Lane, Clinical and Molecular Retrovirology Section National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, USA PC / MAC
30 Years of HIV: what have we learnt
Brian Gazzard, Chelsea & Westminster Hospital, London, UK PC / MAC

Back to top


Monday 3 November

Inflammation and Immune Recovery
Towards an HIV cure
Steve Deeks, University of California, San Francisco, USA PC / MAC
Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection
John Thornhill, Imperial College London, London, UK PC / MAC
CD4+ cell count recovery in naïve patients initiating cART, who achieved and maintained plasma HIV-RNA suppression
Dominique Costagliola, INSERM and Sorbonne Universités, UPMC, Université, Paris, France PC / MAC
Determinants of IL-6 levels during HIV infection
Álvaro Borges, Copenhagen HIV Programme (CHIP), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark PC / MAC

Investing in the Future: The Work of the Congress HIV Research Trust PC / MAC
Introduction
Robert Souhami, Chair, HIV Research Trust
Orphans of the HIV epidemic: the challenges from toddlerhood to adolescence and beyond…
Mamatha Lala, Committed Communities Development Trust; Wadia Group of Hospitals; Mumbai Smiles; Society for Human and Environmental Development, Mumbai, India

ART and Reproductive Health
Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a subdermal contraceptive implant
Kimberly Scarsi, University of Nebraska Medical Center, Omaha, USA PC / MAC
Darunavir pharmacokinetics throughout pregnancy and postpartum
John Lambert, Mater and Rotunda Hospitals, and University College Dublin, Dublin, Ireland PC / MAC
Does pregnancy increase the risk of ART-induced hepatotoxicity among HIV-positive women?
Susie Huntington, University College London, London, UK PC / MAC
Panel discussion PC / MAC

Ian Weller – Vote of Thanks
Kevin M De Cock, US Centers for Disease Control and Prevention’s Center for Global Health, Atlanta, USA  PC / MAC

Lock Lecture PC / MAC
Introduction
Frank Dunn CBE, President, Royal College of Physicians and Surgeons of Glasgow, Glasgow, UK
From guidelines to action: implementation opportunities and realities
Kevin M De Cock, US Centers for Disease Control and Prevention’s Center for Global Health, Atlanta, USA

Poster Discussion Session: Treatment Strategies PC / MAC
The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART
Ward De Spiegelaere, Ghent University Hospital, Ghent, Belgium
The importance of viral blips and duration of therapy initiated in primary infection in maintaining viral control after stopping cART
Sarah Fidler, Imperial College, London, UK
Tolerability is more important than simplicity for treatment durability (Webcast not available)
Benoit Trottier, Clinique Médicale l’Actuel, Montreal, Canada
Early changes in coagulation but not inflammatory biomarkers under intermittent ART: the randomized ANRS 106 WINDOW trial
Sébastien Gallien, Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France
Should the dose of tenofovir be reduced to 200-250mg/day, when combined with protease inhibitors?
Andrew Hill, University of Liverpool, Liverpool, UK

Poster Discussion Session: Cost effectiveness. STDs and PReP PC / MAC
Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r + 3TC for initial ART in HIV infected adults
José M Gatell, Hospital Clinic-IDIBAPS, Barcelona, Spain
Prices of second-line antiretroviral treatment for middle-income countries inside versus outside sub-Saharan Africa
Andrew Hill, University of Liverpool, Liverpool, UK
Two years of Truvada for pre-exposure prophylaxis utilization in the US
Charlene Flash, Baylor College of Medicine, Medicine, Houston, USA
Increased incidence of sexually transmitted diseases in the recent years: data from the ICONA cohort
Antonella Cingolani, Catholic University, Rome, Italy
Socio-economic factors and virological suppression among people diagnosed with HIV in the UK: results from the ASTRA study
Lisa Burch, University College London, London, UK

First Line Treatment Issues
Choice of initial therapy
Manuel Battegay, University Hospital Basel, Basel, Switzerland PC / MAC
Managing first line failure
David Cooper, University of New South Wales, Sydney, Australia PC / MAC
Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1 infected individuals: 96 week results from FLAMINGO
Jean-Michel Molina, Saint-Louis Hospital and University of Paris, Paris, France PC / MAC
More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV cohort
Casper Rokx, Erasmus University Medical Center, Rotterdam, The Netherlands PC / MAC
Panel discussion

Antiretroviral Therapy: Case Session PC / MAC
Case-based discussion held in collaboration with the International Antiviral Society-USA (ISA-USA)
Moderator: Roy Gulick, Weill Medical College of Cornell University, New York, USA
Case 1: When and what to start
Pedro Cahn, Huesped Fundacion, Buenos Aires, Argentina
Case 2: Treatment experienced patient
William Powderly, Washington University School of Medicine, St Louis, USA
Case 3: Pre-exposure Prophylaxis
Jean-Michel Molina, Saint-Louis Hospital and University of Paris, Paris, France
Panel: Pedro Cahn
Simon Collins, UK Community Advisory Board (UK-CAB)/i-Base, UK
Roy Gulick
James Hakim, University of Zimbabwe, Harare, Zimbabwe
Jean-Michel Molina
Cristina Mussini, University of Modena, Modena, Italy
William Powderly

Back to top


Tuesday 4 November

Making resources for health care count: what is the optimal way of managing HIV?
In collaboration with the British HIV Association (BHIVA)
Welcome and Introduction
David Asboe, Chelsea and Westminster Hospital, London, UK 
Rational allocation of resources available for health care: understanding cost effectiveness analysis
Andrew Briggs, University of Glasgow, Glasgow, UK PC / MAC
The challenge: streamlining HIV treatment and care while improving outcomes
Nathan Clumeck, Free University of Brussels, Brussels, Belgium PC / MAC
Models of care and delivery
Jens Lundgren, University of Copenhagen, Copenhagen, Denmark PC / MAC
Integrated care pathways and task shifting
Linda Panton, Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, UK
PC / MAC
Enhancing patient self-management
Alain Volny-Anne, Paris, France PC / MAC
Predicted savings to the UK National Health Service from switching to generic antiretrovirals, 2014–2018
Andrew Hill, University of Liverpool, Liverpool, UK PC / MAC
Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patients (Webcast not available)
Simon Walker, Centre for Health Economics, University of York, York, UK
Panel discussion PC / MAC

Hepatitis C
Hepatitis C, from screening to treatment, a revolution
Karine Lacombe, Infectious and Tropical Diseases, Saint-Antoine Hospital, Paris, France PC / MAC
Safety and efficacy of ombitasvir-450/r and dasabuvir and ribavirin in HCV/HIV-1 coinfected patients receiving atazanavir or raltegravir ART regimens
Roger Trinh, Antiviral Global Project Team, AbbVie Inc., North Chicago, USA PC / MAC
Discussion

Great New Hep C Drugs – But Who Can Afford Them? 
In collaboration with the European AIDS Treatment Group (EATG)
Welcome, introduction and overview of where we are with new hepatitis C direct acting antiretrovirals
Tracy Swan, Treatment Action Group, New York, USA PC / MAC
What issues are there to access to new drugs in Southern Europe
Diego García, European AIDS Treatment Group, Brussels, Belgium and Foro Español de Activistas en Tratamientos del HIV (FEAT), Seville, Spain PC / MAC
Issues in relation to generics and their availability and use
Pauline Londeix, Paris, France PC / MAC
Panel discussion
Closing remarks PC / MAC
Brian West, European AIDS Treatment Group, Brussels, Belgium and Edinburgh, UK

When East meets West: Issues for HIV care across Europe
In collaboration with the International AIDS Society (IAS)
Drug use, HIV, HCV and TB: major interlinked challenges in Eastern Europe and Central Asia
Michel Kazatchkine, United Nations Special Envoy for HIV/AIDS in Eastern Europe and Central Asia, Geneva, Switzerland PC / MAC
HIV epidemic in Russia and neighbouring countries
Vadim Pokrovskiy, Federal AIDS Centre, Moscow, Russia PC / MAC
Treatment and care of TB across Europe
Ole Kirk, Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark PC / MAC
Regional differences in self-reported HIV care and management in the EuroSIDA study
Kamilla Grønborg Laut, CHIP, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark PC / MAC
Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America
Anne Marie W Efsen, Copenhagen Centre for Health and Infectious Disease Research, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
PC / MAC
The cascade of HIV care in Russia, 2011–2013
Anastasia Pokrovskaya, Central Scientific Research Institute of Epidemiology, Russian Federal AIDS Centre, Moscow, Russian Federation PC / MAC
Large disparities in HIV treatment cascades between eight European and high-income countries – analysis of break points
Alice Raymond, Imperial College London, London, UK PC / MAC
Panel discussion
Panellist: Andrzej Horban, Warsaw, Poland

Back to top


Wednesday 5 November

Co-morbidities and Complications Part I
Management of drug resistant TB in patients with HIV co-infection
Graeme Meintjes, University of Cape Town, Cape Town, South Africa PC / MAC
CD4 cell count and the risk of infective and non-infective serious non-AIDS events in HIV-infected persons seen for care in Italy
Giordano Madeddu, Unit of Infectious Diseases, University of Sassari, Sassari, Italy PC / MAC
Predictive value of Prostate Specific Antigen for prostate cancer: a nested case control study in EuroSIDA
Leah Shepherd, University College London, London, UK PC / MAC
Effects of age on symptom burden, mental health and quality of life amongst people with HIV in the UK
Jennifer McGowan, University College London, London, UK PC / MAC
Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study
Colette Smith, University College London, London, UK PC / MAC
Panel discussion

Co-morbidities and Complications Part II
Adverse events: ART and the kidney: alterations in renal function and renal toxicity
Frank Post, King’s College London, London, UK PC / MAC
A clinically useful risk-score for chronic kidney disease in HIV infection (Webcast not available)
Amanda Mocroft, University College London, London, UK
Cardiovascular risk evaluation of HIV-infected patients in a case control study: comparison of the D:A:D and Framingham equations
Samuel Markowicz, CHU Saint-Pierre, Brussels, Belgium PC / MAC
Gender differences in HIV-positive persons in use of cardiovascular disease-related interventions: D:A:D study
Camilla Ingrid Hatleberg, Rigshospitalet, University of Copenhagen, CHIP, Department of Infectious Diseases, Copenhagen, Denmark PC / MAC
Panel discussion

Poster Discussion Session: Adverse Events PC / MAC
Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC
Roger Paredes, Hospital Universitari Germans Trias i Pujol, IrsiCaixa Foundation, Universitat de Vic, Barcelona, Spain
Rates of cardiovascular events and deaths are associated with advanced stages of HIV-infection: results of the HIV HEART Study 7.5 year follow-up
Stefan Esser, University Hospital Essen, Dermatology and Venerology, Essen, Germany
Higher rates of metabolic syndrome among women taking zidovudine as compared to tenofovir in rural Africa: preliminary data from the CART-1 study
Niklaus Daniel Labhardt, Swiss Tropical and Public Health Institute, Department of Medical and Diagnostic Services, Basel, Switzerland
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
Silvia Costarell, San Gerardo Hospital, Infectious Diseases, Monza, Italy
Nephrolithiasis and renal failure among patients exposed to atazanavir, other PIs and PI-free regimens
Angelina Villasis Keever, Bristol-Myers Squibb, Plainsboro, USA
Long term fat redistribution in ARV-nave HIV+ pts initiating a non-thymidine containing regimen in clinical practice
Daniel Podzamczer, Hospital Universitari de Bellvitge, Infectious Diseases, Barcelona, Spain

Poster Discussion Session: Virology and the Brain PC / MAC
Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure
Anna Schultze, University College London, London, UK
HIV-1 group O integrase displays higher susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M
Agnès Depatureaux, McGill AIDS Center, Lady Davis Institute, Jewish General Hospital, Montreal, Canada
Protease mutations emerging on darunavir in protease inhibitor-nave and experienced patients in the UK
Kate El Bouzidi, University College London, London, UK
DRV concentrations and viral load in CSF in pts on DRV/r 600/100 or 800/100mg once daily plus two NRTI
Daniel Podzamczer, Hospital Universitari de Bellvitge, Infectious Diseases, Barcelona, Spain
Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600mg once daily; a randomised controlled trial
Alan Winston, Imperial College London, London, UK
Viro-immunological characterization of naïve patients with high cerebrospinal fluid HIV RNA
Francesca Bai, University of Milan, San Paolo Hospital, Milan, Italy

Resistance and Tropism
Resistance: what’s new and on the horizon, and a time to teach old dogs new tricks?
Jonathan Schapiro, National Hemophilia Center, Tel Aviv, Israel PC / MAC
The R263K mutation in HIV integrase that is selected by dolutegravir (DTG) may actually prevent clinically relevant resistance to this compound
Mark Wainberg, McGill University AIDS Centre, Jewish General Hospital, Montreal, Canada PC / MAC
First prospective comparison of genotypic vs. phenotypic tropism assays in predicting virologic responses to maraviroc (MVC) in a phase 3 study: MODERN
James Demarest, ViiV Healthcare, Research Triangle Park, USA PC / MAC
Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study
Roger Paredes, irsiCaixa AIDS Research Institute, Barcelona, Spain PC / MAC
Panel discussion

Management of Co-morbidities PC / MAC
Case-based discussion held in collaboration with the European AIDS Clinical Society (EACS)
Moderators:Nina Friis-Møller, Odense University Hospital, Odense, Denmark
Patrick Mallon, School of Medicine & Medical Science, Dublin, Ireland

Cases:Prevention and Management of Anal Cancer
Bone
Pulmonary Disease
Management Issues in People Who Use Drugs

Panel:Mark Bower, Chelsea and Westminster Hospital NHS Foundation Trust,
London, UK
Juliet Compston, Cambridge University Hospital, Cambridge, UK
Nikos Dedes, Postive Voice, Athens, Greece
Déborah Konopnicki, Saint-Pierre University Hospital, Brussels, Belgium
Rob Miller, University College London, London, UK
Mina Psichogiou, Athens, Greece

Back to top


Thursday 6 November

ARV-based Prevention
Treatment as prevention: unanswered questions and progress to date
Stefano Vella, Istituto Superiore Di Sanita’, Rome, Italy PC / MAC
A community perspective on PrEP
Simon Collins, UK Community Advisory Board (UK-CAB)/i-Base, London, UK PC / MAC
Panel discussion

ART Strategies
Efavirenz (EFV) 400 mg daily remains non-inferior to 600 mg: 96 week data from the double-blind, placebo-controlled ENCORE1 study
Dianne Carey, The Kirkby Institute, University of New South Wales, Sydney, Australia PC / MAC
Effectiveness of a reduced dose of efavirenz plus 2 NRTIs as maintenance antiretroviral therapy with the guidance of therapeutic drug monitoring
Chien-Chung Hung, National Taiwan University Hospital, Internal Medicine, Taipei City, Taiwan PC / MAC
The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues for patients with HIV-1 RNA below 50 copies/mL
and
Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues

Andrea Antinori, National Institute of Infectious Diseases, Rome, Italy PC / MAC
Rate of viral load failure over time in people on ART in the UK Collaborative HIV Cohort (CHIC) study
Jemma O’Connor, University College London, London, UK PC / MAC

New HIV Drugs
HIV treatment 2020: what will it look like?
Roy Gulick, Weill Medical College of Cornell University, New York, USA PC / MAC
HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 subgroup analysis
and
Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 analysis

Max Lataillade, HIV Drug Development, Bristol-Myers Squibb, Wallingford, USA PC / MAC
Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc
Victor Kramer, McGill University AIDS Centre, Jewish General Hospital, Montreal, Canada PC / MAC
48-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naïve HIV-Infected patients
Jose Gatell, Hospital Clinic, University of Barcelona, Barcelona, Spain PC / MAC

Closing Remarks PC / MAC
Andrew N Phillips, University College London, London, UK
and
Brian West, European AIDS Treatment Group (EATG)

Back to top


Webcasts and Abstracts
Webcasts and links to abstracts published from previous meetings are available by visiting the Congress archive section of this site.

Back to top